Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Vaccines & Immunizations








Novavax COVID-19 Vaccine Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events										Related Pages
										On This PagePersons Aged 12 – 17 Years
Local Reactions
Systemic Reactions
Unsolicited Adverse Events
Serious Adverse EventsPersons Aged ≥18 Years
Local Reactions
Systemic Reactions
Unsolicited Adverse Events
Serious Adverse EventsPersons Aged 12-17 years
Local Reactions
Local reactions were reported by the majority of vaccine recipients and at higher rates than placebo recipients (75.3% vs 20.6% after dose 2). Pain/tenderness at the injection site was the most common and most severe local reaction among vaccine recipients and reported more frequently after dose 2 than after dose 1. Injection site redness and swelling following either dose were reported less frequently but were more common after dose 2 than dose 1. There were no grade 4 local reactions reported. Overall the median time to onset for local reactions was 1-3 days. The median duration of local reactions was 1-3 days in the vaccine group. (Table 1).Table 1. Local reactions in persons ages 12-17 years, Novavax NVX-CoV2373 COVID-19 vaccine and placebo
Table 1. Local reactions in persons ages 12-17 years, Novavax NVX-CoV2373 COVID-19 vaccine and placebo
Dose 1
Dose 2NVX-CoV2373
N=1448
Placebo
N=726
NVX-CoV2373
N=1394
Placebo
N=686Any Local, n (%)Any
948 (65.5)
207 (28.5)
1050 (75.3)
141 (20.6)Grade 3
22 (1.5)
5 (0.7)
118 (8.5)
4 (0.6)Grade 4
0
0
0
0Rednessa, n (%)Any
15 (1.0)
5 (0.7)
104 (7.5)
0Grade 3
0
0
10 (0.7)
0Grade 4
0
0
0
0Swellinga, n (%)Any
20 (1.4)
3 (0.4)
111 (8.0)
1 (0.2)Grade 3
0
1 (0.1)
8 (0.6)
0Grade 4
0
0
0
0Painb/tendernessc, n (%)Any
945 (65.3)
204 (28.1)
1045 (75.0)
141 (20.6)Grade 3
22 (1.5)
4 (0.55)
108 (7.8)
4 (0.6)Grade 4
0
0
0
0
a Grade 3: > 10 cm; and Grade 4: Necrosis or exfoliative dermatitis (redness only)
b Grade 3: Any use of narcotic pain reliever or prevents daily activity; and Grade 4: ER visit or hospitalization.
c Grade 3: Significant discomfort at rest; and Grade 4: ER visit or hospitalization.Systemic Reactions
Systemic reactions were reported by the majority of vaccine recipients and at higher rates than placebo recipients. The frequency of systemic reactions was higher after dose 2 than dose 1 (74.5% vs 55.3%); the severity of systemic reactions was also higher after dose 2 than dose 1 (3.7% vs 22.0% reporting reactions of grade 3 or higher). Fatigue/malaise were the most common systemic reaction (57.9% after dose 2). Fever was reported by 16.9% of vaccine recipients following dose 2. The majority of systemic reactions were mild or moderate in severity. Following Dose 2, 21.8% of participants reported any severe systemic reaction; the most frequently reported severe systemic reactions were fatigue/malaise and myalgia. Grade 4 fever (>40.0°C) was reported by two vaccine recipients after dose 1. Following dose 2, there was one report of grade 4 headache and one report of grade 4 nausea/vomiting among vaccine recipients. For systemic reactions, the median time to onset was between 1 and 3 days after vaccination and persisted for 1-2 days. (Table 2)Table 2. Systemic reactions in persons aged 12-17 years, Novavax NVX-CoV2373 COVID-19 vaccine and placebo
Table 2. Systemic reactions in persons aged 12-17 years, Novavax NVX-CoV2373 COVID-19 vaccine and placebo
Dose 1
Dose 2NVX-CoV2373
N=1448
Placebo
N=726
NVX-CoV2373
N=1394
Placebo
N=686Any systemic eventAny
800 (55.3)
296 (40.8)
1038 (74.5)
198 (28.9)Severe
52 (3.6)
25 (3.4)
304 (21.9)
23 (3.4)Grade 4
2 (0.1)
0
2 (0.1)
0Fevera, n (%)Any
11 (0.8)
5 (0.7)
235 (16.9)
1 (0.2)Grade 3
1 (0.1)
0
31 (2.2)
0Grade 4
2 (0.1)
0
0
0Fatigue/malaiseb, n (%)Any
418 (28.9)
142 (15.7)
807 (57.9)
113 (16.5)Grade 3
33 (2.3)
13 (1.8)
223 (16.0)
13 (1.9)Grade 4
0
0
0
0Headachec, n (%)Any
440 (30.4)
181 (24.9)
793 (56.9)
119 (17.4)Severe
13 (0.9)
12 (1.7)
87 (6.2)
14 (2.0)Grade 4
0
0
1 (<0.1)
0Nausea/vomitingd, n (%)Any
113 (7.8)
56 (7.7)
277 (19.9)
33 (4.8)Grade 3
2 (0.1)
3 (0.4)
14 (1.0)
3 (0.4)Grade 4
0
0
1 (0.1)
0Muscle painb, n (%)Any
492 (34.0)
114 (15.7)
683 (49.0)
82 (12.0)Grade 3
17 (1.2)
4 (0.6)
104 (7.5)
6 (0.9)Grade 4
0
0
0
0Joint painb, n (%)Any
102 (7.0)
35 (4.8)
226 (16.2)
21 (3.1)Grade 3
6 (0.4)
1 (0.1)
40 (2.9)
2 (0.3)Grade 4
0
0
0
0
aGrade 3: 39.0 to 40°C/102.1 to 104°F; Grade 4: >40°C/ >104°F.
bGrade 3: Significant; prevents daily activity; Grade 4: ER visit or hospitalization.
c Grade 3: Significant; any use of narcotic pain reliever or prevents daily activity; Grade 4: ER visit or hospitalization.
d Grade 3: Prevents daily activity, requires outpatient intravenous (IV) hydration; Grade 4: ER visit or hospitalization for hypotensive shock.Unsolicited Adverse Events
Unsolicited adverse events were collected from dose 1 to 28 days post-dose 2. Frequencies of unsolicited adverse events were similar between the vaccine group (15.5%) and placebo group (15.3%). The most frequently reported (>1.0%) unsolicited AEs among vaccine recipients were consistent with common conditions in adolescents, including nasal congestion, cough, and oropharyngeal pain. Non-serious unsolicited AEs considered related by the investigator were reported by 2.9% of participants in the vaccine arm and 0.8% of participants in the placebo arm. The most frequently reported related AEs in the vaccine arm included lymphadenopathy-related events, chills, diarrhea, and decreased appetite. Additional related adverse events were consistent with local and systemic reactogenicity. Lymphadenopathy-related events (lymphadenopathy, axillary pain, and lymph node pain) were reported by 0.9% of participants in the vaccine arm and 0% of participants in the placebo arm and are considered plausibly related to vaccination. A plausible biological mechanism and imbalances in the following additional non-serious unsolicited events are suggestive of a causal relationship to vaccine: fatigue (0.5% vaccine recipients vs. 0.0% placebo recipients), decreased appetite (0.3% vaccine recipients vs. 0.0% placebo recipients), arthralgia (0.2% vaccine recipients vs. 0.0% placebo recipients), injection site pruritus (0.2% vaccine recipients vs. 0.0% placebo recipients), and myalgia (0.1% vaccine recipients vs. 0.0% placebo recipients).
Serious Adverse Events
A serious adverse event was defined as: death; life-threatening event; hospitalization or prolongation of existing hospitalization; persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; or a congenital anomaly/birth defect. Serious adverse events were reported by 7 vaccine recipients (0.5%) and 2 placebo recipients (0.2%). FDA determined that none of the events following vaccination were related to study vaccine.
A 16-year-old male experienced myocarditis two days after dose 2 of the post-crossover period of the trial. Based on the timing of onset following vaccination and multiple similar cases of temporally related myocarditis and pericarditis, FDA considers this event related to the vaccine.Persons Aged ≥ 18 Years
Local Reactions
Local reactions were reported by the majority of vaccine recipients and at higher rates than placebo recipients. Vaccine recipients reported higher rates of local reactions after dose 2 than dose 1. The frequency of local reactions was higher in the 18–64 age group than the ≥65 age group (80.9% vs 61.7% after dose 2). Pain/tenderness at the injection site was the most frequent and severe reported solicited local reaction among vaccine recipients. After dose 1, the 18–64 age group reported pain/tenderness more frequently than the ≥65 age group (60.5% vs 37.9%); a similar pattern was observed after dose 2 (80.8% vs 61.4%). Five grade 4 local reactions of pain/tenderness were reported after dose 2. Redness and swelling were reported less frequently, but these reactions were also more common after dose 2. Overall, the median onset of local reactions in the vaccine group was 2 days after either dose, with a median duration of 2 days after dose 1 and 3 days after dose 2. (Table 3, Table 4).Table 3. Local reactions in persons aged 18-64 years, Novavax COVID-19 vaccine and placebo
Table 3. Local reactions in persons aged 18-64 years, Novavax COVID-19 vaccine and placebo
Dose 1
Dose 2NVX-CoV2373
N=15884
Placebo
N=7868
NVX-CoV2373
N=15148
Placebo
N=7361Any Local, n (%)Any
9633 (60.7)
1722 (21.9)
12261 (80.9)
1637 (22.2)Grade 3
182 (1.2)
19 (0.2)
1084 (7.2)
22 (0.3)Grade 4
0
0
5 (<0.1)
1 (<0.1)Paina/Tendernessb, n (%)Any
9604 (60.5)
1706 (21.7)
12234 (80.8)
1623 (22.1)Grade 3
174 (1.1)
17 (0.2)
951 (6.3)
20 (0.3)Grade 4
0
0
5 (<0.1)
1 (<0.1)Rednessc, n (%)Any
151 (1.0)
21 (0.3)
1040 (6.9)
26 (0.4)Grade 3
3 (<0.1)
0
134 (0.9)
2 (<0.1)Grade 4
0
0
0
0Swellingd, n (%)Any
137 (0.9)
24 (0.3)
943 (6.2)
22 (0.3)Grade 3
6 (<0.1)
3 (<0.1)
82 (0.5)
1 (<0.1)Grade 4
0
0
0
0
a Grade 3: Any use of narcotic pain reliever or prevents daily activity; and Grade 4: Emergency room visit or hospitalization.
b Grade 3: Significant discomfort at rest; Grade 4: ER visit or hospitalization.
c Grade 3: >10 cm; Grade 4: Necrosis or exfoliative dermatitis.
d Evaluated and graded using the functional scale as well as the actual measurement; Grade 3: >10 cm or prevents daily activity; Grade 4: Necrosis.Table 4. Local reactions in persons aged ≥65 years, Novavax COVID-19 vaccine and placebo
Table 4. Local reactions in persons aged ≥65 years, Novavax COVID-19 vaccine and placebo
Dose 1
Dose 2NVX-CoV2373
N=2251
Placebo
N=1114
NVX-CoV2373
N=2048
Placebo
N=978Any Local, n (%)Any
861 (38.3)
178 (16.0)
1263 (61.7)
165 (16.9)Grade 3
14 (0.6)
3 (0.3)
57 (2.8)
2 (0.2)Grade 4
0
0
0
0Paina/Tendernessb, n (%)Any
854 (37.9)
175 (15.7)
1258 (61.4)
161 (16.5)Grade 3
13 (0.6)
3 (0.3)
43 (2.1)
1 (0.1)Grade 4
0
0
0
0Rednessc, n (%)Any
16 (0.7)
5 (0.5)
99 (4.8)
4 (0.4)Grade 3
0
0
7 (0.3)
0Grade 4
0
0
0
0Swellingd, n (%)Any
18 (0.8)
1 (0.1)
111 (5.4)
4 (0.4)Grade 3
1 (<0.1)
0
8 (0.4)
1 (0.1)Grade 4
0
0
0
0
aGrade 3: Any use of narcotic pain reliever or prevents daily activity; and Grade 4: Emergency room visit or hospitalization.
bGrade 3: Significant discomfort at rest; Grade 4: ER visit or hospitalization.
cGrade 3: >10 cm; Grade 4: Necrosis or exfoliative dermatitis.
d Evaluated and graded using the functional scale as well as the actual measurement; Grade 3: >10 cm or prevents daily activity; Grade 4: Necrosis.Systemic Reactions
Systemic reactions were reported at higher rates than placebo recipients for both age groups and after both doses. The frequency of systemic reactions was higher in the 18-64 age group than the ≥65 age group (72.1% vs 48.7% after dose 2). Within each age group, the frequency and severity of systemic reactions was higher after dose 2 than dose 1. For both age groups, fatigue/malaise, headache and muscle pain were the most commonly reported systemic reactions. The majority of systemic reactions were mild or moderate in severity, after both doses and in both age groups. Fever was more common after the second dose and in the younger group (6.2%) compared to the older group (2.0%). Among vaccine recipients, the median onset of systemic reactions was 2 days after either dose, with a median duration of 1 day. Grade 4 fever (>40.0°C) was reported by four vaccine recipients after dose 1 and two vaccine recipients after dose 2. Grade 4 systemic reactions after dose 1 and dose 2 in the 18–64 age group were: headache, fatigue, muscle pain, joint pain, nausea/vomiting, and malaise; see table 3 for details. One report of grade 4 headache after dose 1 and one report each of grade 4 headache and grade 4 joint pain were reported after dose 2 in the ≥65 age group (Table 5, Table 6)Table 5. Systemic reactions in persons aged 18-64 years, Novavax COVID-19 vaccine and placebo
Table 5. Systemic reactions in persons aged 18-64 years, Novavax COVID-19 vaccine and placebo
Dose 1
Dose 2NVX-CoV2373
N=15884
Placebo
N=7868
NVX-CoV2373
N=15148
Placebo
N=7361Any systemic, n (%)Any
7889 (49.7)
3242 (41.2)
10922 (72.1)
2714 (36.9)Grade 3
383 (2.4)
175 (2.2)
1968 (13.0)
155 (2.1)Grade 4
14 (0.1)
4 (0.1)
16 (0.1)
5 (0.1)Fevera, n (%)Any
56 (0.4)
31 (0.4)
941 (6.2)
16 (0.2)Grade 3
7 (<0.1)
7 (0.1)
60 (0.4)
2 (<0.1)Grade 4
4 (<0.1)
1 (<0.1)
2 (<0.1)
0Headacheb, n (%)Any
4158 (26.2)
1866 (23.7)
7128 (47.1)
1492 (20.3)Grade 3
132 (0.8)
58 (0.7)
492 (3.3)
36 (0.5)Grade 4
4 (<0.1)
1 (<0.1)
5 (<0.1)
2 (<0.1)Fatigue/malaisec, n (%)Any
4892 (30.8)
2095 (26.6)
8825 (58.3)
1889 (25.7)Grade 3
249 (1.6)
113 (1.4)
1591 (10.5)
114 (1.6)Grade 4
8 (0.1)
1 (<0.1)
7 (0.1)
3 (<0.1)Muscle painc, n (%)Any
3827 (24.1)
1073 (13.6)
7682 (50.7)
900 (12.2)Grade 3
79 (0.5)
31 (0.4)
805 (5.3)
28 (0.4)Grade 4
2 (<0.1)
1 (<0.1)
5 (<0.1)
4 (0.1)Joint painc, n (%)Any
1260 (7.9)
522 (6.6)
3542 (23.4)
504 (6.9)Grade 3
49 (0.3)
25 (0.3)
393 (2.6)
22 (0.3)Grade 4
1 (<0.1)
0
5 (<0.1)
2 (<0.1)Nausea/Vomitingd, n (%)Any
1069 (6.7)
466 (5.9)
1822 (12.0)
417 (5.7)Grade 3
18 (0.1)
7 (0.1)
26 (0.2)
7 (0.1)Grade 4
4 (<0.1)
2 (<0.1)
7 (0.1)
2 (<0.1)
aAny: ≥38.0°C/100.4°F; Grade 3: 39.0 to 40°C/102.1 to 104°F; Grade 4: >40°C/>104°F.
bGrade 3: Significant; any use of narcotic pain reliever or prevents daily activity; Grade 4: ER visit or hospitalization.
c Significant; prevents daily activity; Grade 4: ER visit or hospitalization.
d Grade 3: Prevents daily activity, requires outpatient IV hydration; Grade 4: ER visit or hospitalization for hypotensive shock.Table 6. Systemic reactions in persons aged ≥65 years, Novavax COVID-19 vaccine and placebo
Table 6. Systemic reactions in persons aged ≥65 years, Novavax COVID-19 vaccine and placebo
Dose 1
Dose 2NVX-CoV2373
N=2251
Placebo
N=1114
NVX-CoV2373
N=2048
Placebo
N=978Any systemic, n (%)Any
725 (32.2)
351 (31.5)
998 (48.7)
276 (28.2)Grade 3
36 (1.6)
12 (1.1)
90 (4.4)
15 (1.5)Grade 4
1 (<0.1)
0
2 (0.1)
0Fevera, n (%)Any
8 (0.4)
3 (0.3)
40 (2.0)
7 (0.7)Grade 3
1 (<0.1)
0
2 (0.1)
1 (0.1)Grade 4
0
0
0
0Headacheb, n (%)Any
344 (15.3)
184 (16.5)
502 (24.5)
144 (14.7)Grade 3
12 (0.5)
4 (0.4)
18 (0.9)
2 (0.2)Grade 4
1 (<0.1)
0
1 (0.1)
0Fatigue/malaisec, n (%)Any
444 (19.7)
202 (18.1)
714 (34.9)
182 (18.6)Grade 3
23 (1.0)
5 (0.5)
68 (3.3)
13 (1.3)Grade 4
0
0
0
0Muscle painc, n (%)Any
284 (12.6)
125 (11.2)
561 (27.4)
102 (10.4)Grade 3
3 (0.1)
4 (0.4)
32 (1.6)
2 (0.2)Grade 4
0
0
0
0Joint painc, n (%)Any
139 (6.2)
71 (6.4)
271 (13.2)
63 (6.4)Grade 3
4 (0.2)
4 (0.4)
16 (0.8)
2 (0.2)Grade 4
0
0
1 (0.1)
0Nausea/Vomitingd, n (%)Any
81 (3.6)
32 (2.9)
108 (5.3)
35 (3.6)Grade 3
0
0
3 (0.2)
0Grade 4
0
0
0
0
aAny: ≥38.0°C/100.4°F; Grade 3: 39.0 to 40°C/102.1 to 104°F; Grade 4: >40°C/>104°F.
bGrade 3: Significant; any use of narcotic pain reliever or prevents daily activity; Grade 4: ER visit or hospitalization.
c Significant; prevents daily activity; Grade 4: ER visit or hospitalization.
d Grade 3: Prevents daily activity, requires outpatient IV hydration; Grade 4: ER visit or hospitalization for hypotensive shock.Unsolicited Adverse Events
Unsolicited AEs were collected from after the first vaccination through 28 days after dose 2. A higher frequency of unsolicited adverse events was reported in the vaccine group compared to the placebo group and was primarily attributed to local and systemic reactogenicity following vaccination. There was a higher frequency of unsolicited AEs among vaccine recipients in the older age group (22.7%) compared to the younger age group (18.3%). Imbalances were observed in multiple categories: cardiac failure and cardiomyopathy (0.05% in vaccine group and 0.02% in placebo arm); events consistent with stroke (0.06% in vaccine group and 0.02% in placebo group [3 of 11 events occurred within 15 days of most recent vaccine dose]); pulmonary embolism for the post-crossover period (0.1% in the vaccine group and 0.05 in the placebo group); and cholecystitis (0.05% in the vaccine group and 0.01% in the placebo group). Non-cardiac, non-neurovascular embolic and thrombotic events were balanced; however, 8 participants in the vaccine arm experienced thrombotic/embolic events within 21 days of the most recent vaccine dose, without plausible alternative etiologies.
Serious Adverse Events
Serious adverse events were defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, or resulted in persistent disability or incapacity. The proportions of participants who reported at least one serious adverse event were 1.0% in the vaccine group and 1.1% in the placebo group. The most common serious adverse events occurring at higher rates in the vaccine group than the placebo group were cerebrovascular accident (0.04% vs. 0%), cholecystitis acute (0.03% vs 0%), atrial fibrillation (0.04% vs. 0.02% placebo, pneumonia aspiration (0.02% vs. 0%), spontaneous abortion (0.02% vs. 0%). FDA judged one serious adverse event of angioedema as potentially related to vaccination. In evaluation of potential harms, cases of myocarditis or pericarditis were detected during Novavax COVID-19 clinical trials. Reports of myocarditis or pericarditis were also identified during postauthorization use of Novavax COVID-19 vaccine in countries outside the United States. Ongoing vaccine safety surveillance in the United States and international will help assess the possible risk for Novavax COVID-19 vaccine-associated myocarditis or pericarditis.
Data source: FDA briefing documentTop of Page
							
					
							Last Reviewed:  August 31, 2022						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeCOVID-19 Vaccination
Product Info by U.S. Vaccineplus icon
EUA
EUI
Interim Clinical Considerationsplus icon
Use of COVID-19 Vaccines in the U.S.
Use of COVID-19 Vaccines in the U.S.: Appendices
FAQs for the Interim Clinical Considerations
Myocarditis and Pericarditis Considerations
Clinical Care
Provider Requirements and Support
Vaccine Recipient Educationplus icon
Talking with Patients about COVID-19 Vaccination
How to Tailor COVID-19 Information to Your Audience
How to Address COVID-19 Vaccine Misinformation
Health Departments
Planning & Partnerships
6 Things to Know
Equity in Childhood COVID-19 Vaccination
COVID-19 Vaccine Data Systemsplus icon
Overviewplus icon
Vaccine IT Overview
Data Reporting Requirements
Vaccine Administration Management System (VAMS)plus icon
Getting Started in VAMS
General Public User
Resources for Jurisdictions, Clinics, and Organizations
VAMS Program Information
Vaccinate with Confidenceplus icon
What Is Vaccine Confidence?
Vaccine Confidence Strategies
Rapid Community Assessment Guide
COVID-19 Vaccine Confidence Data
12 COVID-19 Vaccination Strategies for Your Community
How to Engage the Arts to Build COVID-19 Vaccine Confidence
Strategies for Reaching People with Limited Access to COVID-19 Vaccines


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue